|
Published by: SMI Publishing, Ltd
Published: Apr. 25, 2007
Table of Contents
- Day One
- 8.00 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Michael Rudolf, Consultant Respiratory Physician and Past Chairman British Thoracic Society COPD Consortium, Ealing Hospital.
- Michael Rudolf, Chairman, British Thoracic Society.
- 9.10 THE GLOBAL ASTHMA AND COPD MARKET
- Market overview
- Increased disease awareness
- Pediatric asthma sector
- Ageing population susceptible to COPD
- Treatment cost analysis
- Future market growth
- Dr Craig Conoscenti, Senior Associate Director, Medical Affairs, Boehringer Ingelheim .
- 9.50 ANALYZING THE CURRENT AND FUTURE TRENDS
- European asthma & therapeutic market
- The story so far
- Market Challenges
- Drivers
- Main players
- What’s next (technologies / competition)
- Paljit Mudhar, Industry Analyst, Frost and Sullivan.
- 10.30 Morning Coffee
- 10.50 DEVELOPMENT AND PRECLINICAL CHARACTERIZATION
- An IL-13 Antagonist
- Rationale for targeting IL-13 in Asthma
- Development of a humanized neutralizing antibody against IL-13
- Preclinical testing of anti-IL-13 therapy in models of respiratory disease
- Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth.
- 11.30 SMALL MOLECULE CRTH2 ANTAGONISTS AS
- Useful therapeutics in allergy
- An overview of the role of CRTH2 in allergy and immunity
- Small molecule antagonists to CRTH2; Challenges of chemistry
- In vivo efficacy of CRTH2 antagonists in animal models of allergic disease
- Pre-clinical and clinical development of CRTH2 antagonists
- Kevin Bacon, Founder, Chief Scientific Officer & Head, Research & Development, Actimis Pharmaceuticals.
- 12.10 TECHNICAL SHOWCASE
- NOVEL RESPIRATORY DRUGS - NOVEL PULMONARY DELIVERY STRATEGIES
- Biophysical Aspects of Lung deposition of inhaled Aerosols
- Patients' Breathing: Deposition not only depends on particle size
- Targeting of Drugs to different lung regions
- Pulmonary Drug Delivery in Asthma and COPD
- Benefits of controlled inhalation through the drug development process
- Axel Fischer, Managing Director, Activaero.
- Gerhard Scheuch, Chief Executive Officer, Activaero.
- 12.20 Networking Lunch
- 1.20 ROLE OF LEUKOCYTE PROTEASES IN RESPIRATORY DISEASES
- Drug discovery: small molecule inhibitors of serine proteases
- Overview of the role of specific leukocyte proteases in asthma and COPD
- Serine proteases as small molecule drug targets
- Novel dual inhibitors of chymase and cathepsin G
- Tryptase inhibitors in atopic diseases
- Structure-based drug design
- Chris Molloy, Sr. Research Fellow and Team Leader, Inflammation & Pulmonary Diseases, Johnson & Johnson.
- 2.00 APPLYING ANTISENSE TO THE THERAPY OF ASTHMA AND COPD
- Experience with TPI-ASM8 and TPI-1100
- Administration and cellular uptake of oligonucleotides in the lungs
- Rationale for using a multitarget approach in asthma and COPD
- Preclinical results with TPI-ASM8 and TPI-1100
- Results with TPI-ASM8 in humans
- Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals Inc.
- 2.40 SUPPRESSING MUCUS DEVELOPMENT IN RESPIRATORY DISEASE
- Novel inhibitors of mucus hypersecretion
- Role of mucus in respiratory disease
- Mechanisms for mucus production
- A protein pharmacophore that inhibits cell secretion
- Inhibition of mucus production
- Summary and conclusions
- Dr Charles R Penn, Chief Operating Officer, Syntaxin .
- 3.20 Afternoon Tea
- 3.40 AIRWAY REMODELING IN PULMONARY FIBROSIS
- Professor Geoffrey Laurent, Director, Centre For Respiratory Research.
- 4.20 EMERGING NOVEL TREATMENTS
- Targeting complement as a therapeutic for asthma
- Review of the role of complement in inflammation
- Therapeutic approaches to controlling complement activation
- Role of complement in asthma
- New therapeutics for asthma
- Dr Woodruff Emlen, CEO, Taligen Therapeutics.
- 5.00 FROM BENCH TO BEDSIDE
- The challenge of Translational Research for novel Asthma and COPD therapeutics
- Dr Chris Compton, Executive Director Clinical R & D, Pfizer.
- Dr Chris Compton, Executive Director Clinical R & D, Pfizer.
- 5.40 Chairman’s Closing Remarks and Close of Day One
- Day Two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust.
- 9.10 REDUCING MORTALITY IN COPD
- An achievable goal
- COPD is the only chronic disease where the incidence is increasing and is predicted to be the third cause of mortality by 2020
- COPD is both an airways and a systemic disease, associated with co-morbidities.
- To date, only non-pharmacological interventions (eg smoking cessation, LTOT) have been shown to reduce mortality in COPD
- Data from the TORCH and INSPIRE studies indicate that Seretide (LABA/ICS combination therapy) provides a survival benefit in COPD patients
- The underlying mechanisms of this effect may provide insights into future targets to improve the mortality risk in COPD
- Dr Malcolm Johnson, Global Director, Respiratory Science, Respiratory Medicines Development Centre, GlaxoSmithKline.
- 9.50 DEVELOPMENT AND USE OF BIOMARKERS IN ASTHMA & COPD TO HELP ACCELERATE DRUG DEVELOPMENT
- Novel Insights into disease processes
- Biomarkers can accelerate early Stop/Go decisions in Asthma & COPD
- Biomarkers are also important in predicting long term outcomes with short term studies
- Disease modification remains a long term challenge in both Asthma and COPD and new insights from biomarkers can help determine new therapeutic strategies
- Biomarkers remain important tools for diseases segmentation, reclassification and patient stratification in both Asthma & COPD
- Examples of such strategies will be presented during the conference
- Dr Thomas Eichholtz, Director of Discovery Medicine, Astrazeneca .
- Dr Harsukh Parmar, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca.
- 10.30 Morning Coffee
- 10.50 DATA QUALITY THROUGH STANDARDIZATION
- Philip Geronimo, Senior Education Director, VIASYS .
- 11.30 BIOMARKERS OF INFLAMMATION IN ASTHMA & COPD
- Theodore Reiss, Executive Director, Respiratory & Allergy, Merck Research Laboratories*.
- 12.10 LUNG FUNCTION PARAMETERS AND INTERPRETATION
- Old, new, and replacements
- FEV1 remains in-sensitive to small airways changes
- Newer tests have high technical requirements
- Dr Fred Bode, Associate Clinical Director, Medical Science, Hoffmann-La Roche.
- 12.50 Networking Lunch
- 1.50 QUALITY CONTROL OF SPIROMETRY IN GLOBAL STUDIES
- Over reading systems the plus and minus
- Identifying abnormalities and their cause
- Case studies
- Aleck Harrison, Consultant Clinical Scientist, AJH Partners.
- 2.30 PATIENT REPORTED OUTCOMES AS COMPARED TO LUNG FUNCTION OUTCOMES
- Two sides of the same coin
- Patient reported outcomes and lung function outcomes are not interchangeable
- Should exacerbations be defined from patient reported outcomes, lung function or intervention?
- The patient’s perspective
- The physician’s perspective
- The regulator’s perspective
- Dr Göran Tornling, Vice President and Chief Medical Officer, Biolipox AB.
- 3.10 Afternoon Tea
- 3.30 CRTH2 A NOVEL TARGET FOR ASTHMA AND ALLERGY
- Role of CRTH2 in allergy inflammation
- Oxagen CRTH2 antagonists
- Antagonists of CRTH2 as an approach to treat disease
- Clinical development status
- Mick Hunter, Director, Drug Discovery, Oxagen.
- 4.10 USE OF CLINICAL ENDPOINTS OTHER THAN LUNG FUNCTION IN COPD CLINICAL STUDIES
- COPD is predominantly regarded as a chronic airway disease and so most clinical studies focus on measurement of lung function as a primary endpoint
- It is now recognized that COPD patients suffer co-morbidities such as CV, metabolic, GI and orthopaedic disease, which may be important contributors to the overall poor health status of patients
- Treatment of airway disease remains the gold standard for treating COPD. However, targeting the major co-morbidities may be critical in improving health status of COPD patients
- Persistent and/or latent pulmonary hypertension is recognized as a feature in many COPD patients, which can have a debilitating effect on physical activity in these patients
- Alternative clinical endpoints may be better predictors of disease progression in COPD
- Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana Pharma.
- 4.50 Chairman’s Closing Remarks and Close of Day Two
AbstractKim Kuebler, Medical Scientist, Boehringer-Ingelheim
It is estimated that the global annual sales in the asthma and COPD market are due to increase by over $10 billion US dollars within the next 5 years and then remain flat thereafter. Will you make use of this transforming market & increasing potential before it’s too late?
Through a series of case studies from the leading pharmaceutical companies SMi’s 3rd annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine the mortality levels in asthma and COPD, inspect the emerging novel treatments and drug therapies and highlight the development and use of biomarkers through to the use of clinical endpoint in Asthma & COPD.
This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.
OUR EXPERT PANEL OF SPEAKERS INCLUDES:
- Dr Chris Compton, Executive Director Clinical R&D, Pfizer
- Dr Craig S. Conoscenti, Senior Associate Director, Medical Affairs, Boehringer-Inglehiem
- Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline
- Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth
- Stephen Stenglein, Clinical & Regulatory Affairs, Novartis
- Theodore Reiss, Executive Director, Respiratory & Allergy, Merck
- Thomas Eichholtz, Director of Discovery Medicine, Respiratory & Inflammation Research Area, AstraZeneca
- Dr Fred Bode, Associate Clinical Director, F. Hoffmann-La Roche
- Dr Kevin Bacon, Founder, CSO and Head of Research & Development, Actimis Pharmaceuticals
- Dr Christopher Molloy, Senior Research Fellow & Team Leader, Inflammation & Pulmonary Disease, Johnson & Johnson
- Dr Mick Hunter, Director of Drug Discovery, Oxagen
- Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana
- Dr Woodruff Emlen, CEO, Taligen Therapeutics
- Dr Göran Tornling, Vice President & Chief Medical Officer, Biolipox
- Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals
- Peter Kiener D.Phil, Senior Vice President, Research, MedImmune
- Dr Charles R Penn, Chief Operating Officer, Syntaxin
The conference will be chaired by;
- Dr Michael Rudolf, Consultant Respiratory Physician, Ealing Hospital and Past Chairman, British Thoracic Society COPD Consortium
- Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust
If you attend one respiratory conference this year this should be the one! Nowhere else will you find such a diverse speaker line- up, mix of topics and in-depth coverage of the industry!
BENEFITS OF ATTENDING ASTHMA & COPD
- GAIN a valuable insight into the current pipeline developments in the respiratory arena
- IDENTIFY new drug developments and concepts
- REVIEW the clinical endpoints that are currently being accepted
- EXAMINE the development and use of biomarkers in Asthma & COPD
- HEAR case studies from the world leaders in respiratory drug discovery
WHO SHOULD ATTEND ASTHMA AND COPD
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within: - Respiratory Science
- Research & Development
- Inflammation
- Clinical & Regulatory Affairs
- Drug Discovery
- Respiratory Illness
- Inhalation Drug Delivery
- Project Management
- Preclinical Development
- Portfolio Management
- Marketing
WHO WILL YOU MEET AT ASTHMA & COPD?
- A sample of the companies already in attendance includes:
- Abbot Laboratories
- Actimis
- Activaero
- Almirall
- ALTANA
- Amgen
- ARGENTA DISCOVERY
- Astellas Pharma
- Battelle
- Bespak
- Biolipox
- Boehringer Ingelheim
- CRS Clinical Research Services Andernach
- Cyto Kinetics Inc
- F. Hoffmann-La Roche
- GlaxoSmithKline
- i3 Research
- Imperial Innovations
- INDRA
- Johnson & Johnson PRD
- Medimmune
- Merck Research Laboratories
- Merck Serono
- Mundipharma
- Novartis
- Orion Pharma
- Oxagen
- Pfizer
- Pharma Bio-Research Group BV
- Sanofi-Aventis
- Syntaxin
- Taligen Therapeutics
- Teva
- Topigen Pharmaceuticals
- University College London Medical School
- Wood Mackenzie
- Wyeth
- VIASYS Healthcare
- Vitalograph
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
